Fresenius SE & Co. KGaA



Fresenius - the health care group

Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.

The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius KabiFresenius Helios and Fresenius Vamed.

Latest news

Change in Investor Relations Management

Birgit Grund, Senior Vice President of Investor Relations at Fresenius for the past 24 years, plans to leave the Company on March 31, 2015, to pursue a new opportunity. Markus Georgi will succeed Birgit Grund as Senior Vice President of Investor Relations, effective April 1, 2015. He has worked in Investor Relations for more than 15 years and will join Fresenius from Celesio AG, where he is currently Director Investor Relations.

Fresenius refinances its credit agreement – Standard & Poor’s upgrades Fresenius’ credit rating to investment grade

Fresenius has launched a refinancing of the revolving facilities and the term loan A tranches (aggregate volume approx. €3 bn) under its 2013 senior credit agreement. The maturity will be extended by 2 years to June 28, 2020. Given the improved credit profile and favorable bank market conditions, Fresenius’ proposal also includes reduced credit margins.

Standard & Poor’s upgrades Fresenius Medical Care’s credit rating to investment grade

Fresenius Medical Care today announced that Standard & Poor’s has upgraded the corporate credit rating of Fresenius Medical Care from BB+ to BBB- with a stable outlook.

Fresenius Kabi Receives FDA Status Upgrade for US Grand Island Facility

Fresenius Kabi has been informed by the U.S. Food and Drug Administration that its pharmaceutical manufacturing facility in Grand Island, N.Y., has achieved the upgraded status of voluntary action indicated (VAI) following an October 2014 inspection.

Fresenius Medical Care successfully upsizes and extends the maturity of its credit agreement and also extends the maturity of its accounts receivable facility

Fresenius Medical Care has upsized its syndicated credit facility by 850 million U.S. dollar equivalent to a total amount of approximately 4.4 billion U.S. dollar equivalent, with pricing and other conditions more favorable to the company. The amended credit facility consists of revolving facilities and term loans, both U.S. dollar and euro denominated.